[Effect of Lingnan Chen's acupuncture on postmenopausal osteoporosis and serum GH and IGF-1]

What Was Tested

This randomized controlled trial paper looks at IGF-1 LR3.

To compare the therapeutic effect on postmenopausal osteoporosis (PMOP) between Lingnan Chen's needling technique and calcitriol soft capsules and investigate the effect mechanism in view of serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1).

Who Took Part

PubMed tags the participants as women only.

Seventy patients of PMOP were randomized into an observation group (35 cases, 4 cases dropped off ) and a control group (35 cases, 3 cases dropped off ).

Before and after treatment, the bone mineral density (BMD), the levels of serum GH and IGF-1 were assessed in two groups.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

The intervention measures of two groups all lasted 12 weeks.

Before treatment and 4, 8 and 12 weeks after treatment, TCM symptoms score and the MOS item short form health survey (SF-36) score were evaluated and the therapeutic effects were compared between groups.

What Was Measured

The subject headings attached to it are Acupuncture Points, Acupuncture Therapy, Calcitriol, Growth Hormone, Insulin-Like Growth Factor I, Osteoporosis, Postmenopausal and Quality of Life.

Author keywords: Lingnan Chen's acupuncture, insulin-like growth factor-1, postmenopausal osteoporosis and randomized controlled trial (RCT).

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Zhongguo zhen jiu = Chinese acupuncture & moxibustion), a journal based in China.

More context: the IGF-1 LR3 compound page, all human trials.